Skip to main content

Table 1 Key studies of TNF-blocker therapy in rheumatoid arthritis, 52-week follow-up

From: Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future

Therapy Disease stage Reference Primary outcome Radiologic outcome
Infliximab RA Smolen and colleagues [16] ACR20 Modified TSS
Infliximab Early RA Smolen and colleagues [17] ACR20 Modified TSS
Etanercept Early RA Bathon and colleagues [18] ACR20 TSS
Etanercept RA Klareskog and colleagues [19] ACR20 Modified TSS
Etanercept Early RA Kekow and colleagues [20] ACR20 Modified TSS
Adalimumab Early RA Breedveld and colleagues [21] ACR50 Modified TSS
Adalimumab RA Keystone and colleagues [22] ACR20 Modified TSS
Golimumab RA Kremer and colleagues [23] ACR50 Modified TSS
Certolizumab RA Keystone and colleagues [24] ACR20 Modified TSS
  1. ACR20/50, American College of Rheumatology 20%/50% improvement; RA, rheumatoid arthritis; TSS, total Sharp score.